The 16 most recent market catalysts affecting $HUM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
Bill Ackman's public endorsement of Mark Cuban's proposals for transparent drug pricing, which aim to dismantle the traditional PBM model, signals a significant shift in the health…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 65
Humana Reiterates FY26 Adjusted EPS Outlook Of At Least $9
Humana filed an 8-K to reiterate its adjusted EPS outlook of at least $9 for fiscal year 2026. This is a reaffirmation of previously communicated guidance, not new information. It …
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Neutral on Humana, Raises Price Target to $393
This filing indicates that JP Morgan analyst Lisa Gill has maintained a 'Neutral' rating on Humana (HUM) but significantly raised the price target from $316 to $393. This action si…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Morgan Stanley Upgrades Humana to Equal-Weight, Raises Price Target to $370
Morgan Stanley analyst Erin Wright upgraded Humana (HUM) from Underweight to Equal-Weight and raised the price target from $249 to $370. This significant increase in the price targ…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Equal-Weight on Humana, Raises Price Target to $407
Barclays analyst Andrew Mok maintained an 'Equal-Weight' rating on Humana but significantly raised the price target from $344 to $407. This action signals a more optimistic valuati…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Evercore ISI Group Upgrades Humana to Outperform, Raises Price Target to $480
This filing discloses that Evercore ISI Group has upgraded Humana's stock rating and raised its price target. This is a positive development for Humana as it signals increased conf…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Humana, Raises Price Target to $471
Guggenheim analyst Jason Cassorla maintained a 'Buy' rating on Humana and substantially raised the price target from $269 to $471. This significant increase in the price target ind…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Humana shares are trading lower after the company reported Q2 financial results and issued FY26 GAAP EPS guidance below estimates.
Humana's lower-than-expected Q2 results and, more critically, the reduced FY26 GAAP EPS guidance signal potential headwinds for the company's long-term profitability. This could st…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 75
Humana FY2026 Adj EPS expected to be more than $9.00 vs $8.94 Est
Humana has provided an updated outlook for its fiscal year 2026 adjusted EPS, projecting it to be above $9.00, which is slightly higher than the consensus estimate of $8.94. This g…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 65
Humana Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Humana is set to release its Q2 earnings, with analysts projecting strong growth in both EPS and revenue compared to the prior year. This positive outlook is reinforced by several …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Hold on Humana, Raises Price Target to $350
TD Cowen's analyst Ryan Langston maintained a 'Hold' rating on Humana but substantially raised the price target from $211 to $350. This significant increase in the price target, de…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Hold on Humana, Raises Price Target to $415
Truist Securities analyst David Macdonald maintained a 'Hold' rating on Humana but significantly raised the price target from $320 to $415. This action suggests that while the anal…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 85
Humana shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $227 to $502.
This headline represents a significant corporate catalyst for Humana. A major analyst firm like Wells Fargo upgrading a stock from 'Equal-Weight' to 'Overweight' and more than doub…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Wells Fargo Upgrades Humana to Overweight, Raises Price Target to $502
Wells Fargo analyst Stephen Baxter upgraded Humana (HUM) from Equal-Weight to Overweight, while simultaneously raising the price target from $227 to an impressive $502. This move i…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.